Objectives: To investigate predictors of time to metastasis among men treated with androgen deprivation therapy (ADT) for non-metastatic prostate cancer who developed castration-resistant prostate cancer (CRPC) within the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
Results: A total of 256 (56%) men were diagnosed with metastatic disease over a median follow-up of 36 months. Metastasis-free survival was 79%, 65%, 52%, 47% and 41% at 1, 2, 3, 4 and 5 years after CRPC, respectively. In multivariable analysis, Gleason score 8-10 (HR=1.61; P=0.026), receiving primary localized treatment (HR=1.38; P=0.028), higher PSA levels at CRPC diagnosis (logPSA HR=1.64; P<0.001) and PSA doubling time ≤6 months (HR=1.42; P=0.040) were independently associated with shorter time to metastasis. Race, year of CRPC, age and time from ADT to CRPC were not associated with metastasis.
Conclusions:
Among non-metastatic CRPC men, nearly 60% developed metastatic disease during the first 5 years with most of the metastasis occurring within the first 3 years. Higher Gleason score, receiving primary treatment, higher PSA and shorter PSA doubling time were independently associated with shorter time to metastasis. Therefore, these variables can be used to stratify patients according to metastasis risk.
Introduction:
Metastatic prostate cancer poses a great health and economic burden given that metastases are frequently associated with skeletal-related events (SREs) such as pain, pathologic fractures, spinal cord compression and the need for surgery and/or radiotherapy to the bone. 1 To date, only a few treatments have been shown to decrease these complications.
For example, zolendronic acid, 2 denosumab, 3 radium-223, 4 and abiraterone 5 have all been
shown to reduce the incidence of SREs and to prolong the time interval to first SRE in patients with metastatic prostate cancer. Given that bone metastases are frequently asymptomatic in Page 2 of 14 the beginning, early diagnosis of metastatic disease by the use of radiologic studies allows for early institution of these treatments, potentially reducing the incidence of SREs and prolonging the time to first SRE.
Men with non-metastatic castration-resistant prostate cancer (CRPC) have worse prognosis than their hormone-sensitive counterparts and are at a particularly higher risk of developing bone metastasis. 6 Thus, non-metastatic CRPC patients are the ones who theoretically would benefit the most from screening for bone metastasis. Yet, the time to progression to metastatic disease varies from patient to patient. Additionally, most scans used to screen bone metastasis in patients with prostate cancer are negative. 7 Thus, it seems reasonable to tailor the follow-up of these patients according to their risk of disease progression. However, there are only a few studies examining the natural history of these patients. 8, 9 In addition, the factors associated with rapid progression to metastatic disease have been evaluated in a small number of studies with limited sample sizes. [8] [9] [10] [11] Therefore, we sought to investigate the predictors of time to metastasis among men treated with androgen deprivation therapy (ADT) for non-metastatic prostate cancer who developed CRPC within the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. and secondary treatments for prostate cancer were at the discretion of the patient and treating physician. The number, interval and trigger for imaging tests were also at the discretion of the patient and treating physician. Bone metastases were determined based on bone scans or Xrays. Soft tissue metastases were detected by MRI or CT. Imaging tests were read by radiologists who were not blinded to patient demographics, laboratory, radiologic or pathologic results. Imaging tests were coded as positive or negative based upon the radiology report as interpreted by trained personnel. Equivocal scans, given they usually do not prompt a change in management, were considered negative unless confirmed positive by a biopsy.
Methods:

Study population
Statistical analysis
PSA doubling time (PSADT) was calculated as the natural log of two divided by the 
Results:
The median (and IQR) age at CRPC of our sample was 75 (67-81) years. A total of 143 (31%) patients were black. The median (and IQR) PSA at diagnosis of CRPC was 4.3 (2.9- A total of 256 (56%) men developed metastatic disease over a median follow-up of 3 years after CRPC. We detected bone metastases in 89% of men with metastasis, visceral metastasis in 8%, and lymph node metastasis in 17%. Metastasis-free survival was 79%, 65%, 52%, 47% and 41% at 1, 2, 3, 4 and 5 years after CRPC, respectively (Figure 1a) (Table 1) .
Figures 1b to 1e show the individual associations between time to metastasis and PSA levels, Gleason score, primary localized treatment, and PSADT divided into groups. Figure 2 shows the cumulative incidence curve of development of soft tissue metastasis, bone metastasis, or any metastasis. Figure 3 shows a nomogram predicting metastasis-free survival. Supplementary figure 2 depicts the calibration plot depicting comparing the predicted and actuarial metastasis-free probabilities at 4 years. The nomogram's raw and bias-corrected concordance indexes were, respectively, 0.67 and 0.66.
Discussion:
The natural history of patients with non-metastatic CRPC is variable. 13 Many patients rapidly progress to metastatic disease and eventually die of the disease; while others have an indolent progression. At present, there no treatment options for non-metastatic CRPC that have shown a survival benefit. However, patients with asymptomatic metastatic CRPC have been shown to benefit from specific treatments such as docetaxel, 14 sipuleucel-T, 15 and abiraterone plus prednisone, 5 and enzalutamide. 16 Given many patients with documentable metastatic disease to the bone by radiologic studies are asymptomatic, it is reasonable to screen CRPC patients for metastasis in order to institute life-prolonging treatment as early as possible. As such, it is important to determine the factors associated with rapid progression to metastasis in order to individualize the screening for metastatic disease among these patients.
Therefore, we investigated the incidence of metastasis in CRPC patients and the predictors of time from CRPC to metastatic disease among men treated with ADT who developed CRPC.
We found about two thirds of patients developed metastatic disease in the first 5 years after CRPC. Higher biopsy Gleason score, higher PSA and younger age were independent predictors of shorter time to metastasis. We also generated a nomogram to predict the metastasis-free survival probabilities.
A few previous studies have evaluated the natural history of non-metastatic CRPC patients. For example, Smith et al performed an analysis of 201 patients in the placebo group from an aborted randomized trial to evaluate the effects of zoledronic acid on time to first bone Page 6 of 14 metastasis. 9 Later, the same authors used a similar strategy to study 331 subjects in the placebo group of another randomized trial of atrasentan on time to disease progression. 8 In both studies, the median time to metastasis was nearly 30 months, compared to approximately 36 months in our study. In both studies, patients had a significantly higher mean PSA level at baseline (31 and 35 ng/dL) compared to our sample (4.2 ng/dL). In addition, patients were considerably younger (mean age 73 and 73 versus 78 years in our cohort) and had a more remote diagnosis of prostate cancer (mean 6.5 and 7.0 versus 4.3 years prior to entering the study in our cohort). Importantly, patients in these trials were not captured at the time of CRPC diagnosis but were afterwards identified after having a negative bone scan. This is similar to our study which followed men from the initial diagnosis of CRPC. Moreover, their studies used data from patients in clinical trials while we used a clinical cohort. These differences can potentially explain why patients in our study had a longer time to metastasis. Nevertheless, despite the differences across studies the compounded evidence indicates patients with CRPC are at a very high risk for metastasis, with most developing metastases within 36 months.
Patients with CRPC progress to metastatic disease at different rates. Some of the factors associated with rapid progression to metastasis have been previously described.
Similar to our study, Smith at al in their earlier study found higher PSA levels and faster PSA velocity to be associated with shorter time to metastasis in two separate studies. 8, 9 However, different from our findings, Gleason score was not associated with time to metastasis in either of their studies. More recently, a study by Metwali et al found metastasis to be associated with higher PSA levels (at diagnosis and nadir PSA after ADT), rapid alkaline phosphatase rise and shorter PSA doubling times in men with CRPC. 10 Thus, the combined evidence in the literature suggests that PSA level and kinetics may be the most important factors to predict progression to metastatic disease. Thus, the use of PSA levels and kinetics in combination with other predictors such as Gleason score may be useful to stratify patients according to their risk of developing metastatic disease. Consequently, follow-up strategies may be tailored to the risk of metastatic disease where patients at higher risk for metastasis may be screened more frequently than those at a lower risk. This strategy can potentially minimize costs and reduce the exposure to radioactive contrast media in the low-risk group and allow for an early diagnosis of metastatic disease among the high-risk group.
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The current study has several strengths including the large number of CRPC patients from a racially diverse cohort and a relatively long follow-up. However, it is not devoid of limitations. The main limitation is its retrospective nature. Consequently, we were not able to decide when and how bone scans were performed. It is plausible that patients with more advanced and aggressive disease at baseline had more frequent and earlier bone scans compared to those with less advanced and aggressive disease for whom the bone scan may have been deferred to a later point in time. If this hypothesis is true, some patients with worse disease were more likely to be diagnosed with metastasis while a number of patients with more favorable disease may have been excluded from the study given they never had a previous bone scan. Similarly, we had no control over when and how patients were treated with ADT or other therapies. Although these limitations add noise and unwanted variability to the study, they reflect the current clinical practice in the CRPC treatment. Moreover, we were unable to evaluate different ADT schemes (such as continuous and intermittent) as the data was not available for all patients. We were unable to determine the reasons why active primary treatment (surgery or radiotherapy) before CRPC would be associated with faster time to metastasis. It is possible that selection bias and/or confounding factors may the reason for such an association. As such, the causal relationship between primary treatment and time from CRPC to metastasis could not be determined. In addition, given only 250 patients had prostate cancer diagnosis date available we were unable to evaluate time from diagnosis to ADT in multivariable models. Finally, although bone scans are very sensitive to detect metastasis, false positives and negatives do occur, but we were unable to identify them given confirmatory imaging was not available for all patients in our sample. 17 In conclusion, among subjects with non-metastatic CRPC, nearly 70% developed metastatic disease during the first 5 years after CRPC with most of the metastasis occurring within the first 3 years. Higher Gleason score, higher PSA, and shorter PSADT were independently associated with shorter time to metastasis. Therefore, if these results are confirm in future studies, Gleason score, PSA and PSADT can be used to stratify patients according to the risk of metastasis. 
